Biogen Amevive facility approved
Biogen receives FDA approval for 90,000 liter manufacturing plant to produce psoriasis drug Amevive (alefacept). The 250,000 square foot facility, located in Research Triangle Park, N.C., brings Biogen's capacity for mammalian cell products to 106,000 liters; a 90,000 liter facility is under construction by Idec. FDA approved the biologic for marketing in January (1"The Pink Sheet" Feb. 3, 2003, p. 3)...
You may also be interested in...
Biogen will distinguish Amevive in the psoriasis market by emphasizing the biologic's duration of response following FDA approval Jan. 30
Roche is hoping the investigational oral drug can help it expand its presence in breast cancer and break into the prostate cancer market – but the signals are decidedly mixed.
CDRH director Jeff Shuren says the US agency’s device center has been tallying up lessons learned from the COVID-19 pandemic.